Un diagnóstico complejo y de difícil tratamiento | 20 ABR 19

Enfermedad de Parkinson

Tiene las características motoras del parkinsonismo asociadas con los cuerpos de Lewy y la pérdida de neuronas dopaminérgicas en la sustancia negra
7
31
Autor: Kalia LV, Lang AE The Lancet. Volume 386, No. 9996
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 2011; 1: a008862.

2 Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51: 745–52.

3 Marras C, Lang A. Parkinson’s disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry 2013; 84: 409–15.

4 Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40: 1529–34.

5 Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013;80: 276–81.

6 Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 2011; 26: 399–406.

7 Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord 2014; 29: 195–202.

8 Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 2012; 27: 617–26.

9 American Academy of Sleep Medicine. International classifi cation of sleep disorders: diagnostic and coding manual, 2nd edn. Westchester, IL: American Academy of Sleep Medicine, 2005.

10 Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010; 6: 85–95.

11 Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72: 1296–300.

12 Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013; 14: 744–48.

13 Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013; 12: 443–53.

14 Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012; 72: 893–901.

15 Siderowf A, Lang AE. Premotor Parkinson’s disease: concepts and defi nitions. Mov Disord 2012; 27: 608–16.

16 Hely MA, Morris JGL, Reid WGJ, Traffi cante R. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190–99.

17 Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.

18 Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012; 8: 435–42.

19 Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384–86.

20 Alzheimer’s Association. 2014 Alzheimer’s disease facts and fi gures. Alzheimers Dement 2014; 10: e47–e92.

21 Von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005; 15: 473–90.

22 Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Mov Disord 2004; 19: 318–23.

23 Bauso DJ, Tartari JP, Stefani CV, Rojas JI, Giunta DH, Cristiano E. Incidence and prevalence of Parkinson’s disease in Buenos Aires City, Argentina. Eur J Neurol 2012; 19: 1108–13.

24 Okubadejo NU, Bower JH, Rocca WA, Maraganore DM. Parkinson’s disease in Africa: a systematic review of epidemiologic and genetic studies. Mov Disord 2006; 21: 2150–56.

25 Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson’s disease in Asia. J Epidemiol 2009; 19: 281–93.

26 Benamer HTS, de Silva R, Siddiqui KA, Grosset DG. Parkinson’s disease in Arabs: a systematic review. Mov Disord 2008;23: 1205–10.

27 Van Den Eeden SK. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157: 1015–22.

28 De Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006; 5: 525–35.

29 Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009; 72: 432–38.

30 Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014; 29: 1583–90.

31 Ritz B, Lee PC, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 2014; 83: 1396–402.

32 Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med 2010; 4: 701–12.

33 Mortimer JA, Borenstein AR, Nelson LM. Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. Neurology 2012; 79: 1174–80.

34 Foubert-Samier A, Helmer C, Perez F, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 2012; 79: 1615–21.

35 Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012; 71: 776–84.

36 Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identifi ed in families with Parkinson’s disease. Science 1997; 276: 2045–47.

37 Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev 2011;91: 1161–218.

38 Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012; 11: 986–98.

39 Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 2009; 361: 1651–61.

40 Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifi es six new risk loci for Parkinson’s disease. Nat Genet 2014; 46: 989–93.

41 Lee P-C, Bordelon Y, Bronstein J, Ritz B. Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. Neurology 2012; 79: 2061–66.

42 Popat RA, Van Den Eeden SK, Tanner CM, et al. Coff ee, ADORA2A, and CYP1A2: the caff eine connection in Parkinson’s disease. Eur J Neurol 2011; 18: 756–65.

43 Hamza TH, Chen H, Hill-Burns EM, et al. Genome-wide gene-environment study identifi es glutamate receptor gene GRIN2A as a Parkinson’s disease modifi er gene via interaction with coff ee. Plos Genet 2011; 7: e1002237.

44 Goldman SM, Kamel F, Ross GW, et al. Head injury, alpha-synuclein Rep1, and Parkinson’s disease. Ann Neurol 2012; 71: 40–48.

45 Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refi ning the diagnostic criteria. Lancet Neurol 2009; 8: 1150–57.

46 Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 2013; 136: 2419–31.

47 Dickson DW. Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2012; 2: a009258.

48 Masters CL, Kril JJ, Halliday GM, et al. Overview and recent advances in neuropathology. Part 2: Neurodegeneration. Pathology 2011;43: 93–102.

49 Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388: 839–40.

50 Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2012; 9: 13–24.

51 Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology 1999; 52: 1269–71.

52 Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol 2007; 66: 354–62.

53 Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119: 689–702.

54 Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 2010; 119: 703–13.

55 Braak H, Del Tredici K, Rub U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197–211.

56 Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson’s disease. Brain 2009; 132: 2947–57.

57 Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain 2010; 133: 1755–62.

58 Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72: 587–98.

59 Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115: 399–407.

60 Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 2008; 115: 409–15.

61 Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 2003; 62: 644–54.

62 Kovacs GG, Wagner U, Dumont B, et al. An antibody with high reactivity for disease-associated a-synuclein reveals extensive brain pathology. Acta Neuropathol 2012; 124: 37–50.

63 Schulz-Schaeff er WJ. The synaptic pathology of a-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 2010; 120: 131–43.

64 Cremades N, Cohen SIA, Deas E, et al. Direct observation of the interconversion of normal and toxic forms of a-synuclein. Cell 2012;149: 1048–59.

65 Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. a-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 2013; 73: 155–69.

66 Compta Y, Parkkinen L, O’Sullivan SS, et al. Lewy- and Alzheimertype pathologies in Parkinson’s disease dementia: which is more important? Brain 2011; 134: 1493–505.

67 Irwin DJ, Lee VM-Y, Trojanowski JQ. Parkinson’s disease dementia: convergence of a-synuclein, tau and amyloid-ß pathologies. Nat Rev Neurosci 2013; 14: 626–36.

68 Doherty KM, Silveira-Moriyama L, Parkkinen L, et al. Parkin disease: a clinicopathologic entity? JAMA Neurol 2013; 70: 571–79.

69 Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson’s disease. Mov Disord 2012; 27: 831–42.

70 Kalia LV, Lang AE, Hazrati LN, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson’s disease. JAMA Neurol 2015; 72: 100–05.

71 Tansey MG, Goldberg MS. Neuroinfl ammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010; 37: 510–18.

72 Phani S, Loike JD, Przedborski S. Neurodegeneration and infl ammation in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: S207–09.

73 Devine MJ, Gwinn K, Singleton A, Hardy J. Parkinson’s disease and alpha-synuclein expression. Mov Disord 2011; 26: 2160–68.

74 Cookson MR. Cellular eff ects of LRRK2 mutations. Biochem Soc Trans 2012; 40: 1070–73.

75 Dzamko N, Halliday GM. An emerging role for LRRK2 in the immune system. Biochem Soc Trans 2012; 40: 1134–39.

76 Lee S, Imai Y, Gehrke S, Liu S, Lu B. The synaptic function of LRRK2. Biochem Soc Trans 2012; 40: 1047–51.

77 Sanna G, Del Giudice MG, Crosio C, Iaccarino C. LRRK2 and vesicle traffi cking. Biochem Soc Trans 2012; 40: 1117–22.

78 Martin I, Kim JW, Lee BD, et al. Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson’s disease. Cell 2014; 157: 472–85.

79 Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 2004; 44: 595–600.

80 Healy DG, Falchi M, O’Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 2008;7: 583–90.

81 Aasly JO, Vilarino-Guell C, Dachsel JC, et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson’s disease. Mov Disord 2010; 25: 2156–63.

82 Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med 2006; 354: 424–25.

83 Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med 2006;354: 422–23.

84 Zimprich A, Benet-Pages A, Struhal W, et al. A mutation in VPS35,encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89: 168–75.

85 Vilarino-Guell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011; 89: 162–67.

86 Chartier-Harlin M-C, Dachsel JC, Vilarino-Guell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 2011; 89: 398–406.

87 Vilarino-Guell C, Rajput A, Milnerwood AJ, et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet 2014; 23: 1794–801.

88 Funayama M, Ohe K, Amo T, et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson’s disease: a genome-wide linkage and sequencing study. Lancet Neurol 2015; 14: 274–82.

89 Bonifacino JS, Hurley JH. Retromer. Curr Opin Cell Biol 2008;20: 427–36.

90 Tucci A, Charlesworth G, Sheerin U-M, Plagnol V, Wood NW, Hardy J. Study of the genetic variability in a Parkinson’s Disease gene: EIF4G1. Neurosci Lett 2012; 518: 19–22.

91 Schulte EC, Mollenhauer B, Zimprich A, et al. Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson’s disease. Neurogenetics 2012; 13: 281–85.

92 Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5: 355–63.

93 Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 2000; 342: 1560–67.

94 Periquet M, Latouche M, Lohmann E, et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 2003; 126: 1271–78.

95 Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord 2013;28: 14–23.

96 Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6: 652–62.

97 Mccoy MK, Cookson MR. Mitochondrial quality control and dynamics in Parkinson’s disease. Antioxid Redox Signal 2012;16: 869–82.

98 Puschmann A. Monogenic Parkinson’s disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 2013; 19: 407–15.

99 Krebs CE, Karkheiran S, Powell JC, et al. The Sac1 domain of SYNJ1 identifi ed mutated in a family with early-onset progressive parkinsonism with generalized seizures. Hum Mutat 2013;34: 1200–07.

100 Quadri M, Fang M, Picillo M, et al. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset parkinsonism. Hum Mutat 2013; 34: 1208–15.

101 Wilson GR, Sim JC, McLean C, et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with a-synuclein pathology. Am J Hum Genet 2014; 95: 729–35.

102 Butcher NJ, Kiehl T-R, Hazrati L-N, et al. Association between early onset Parkinson disease and 22q11.2 deletion syndrome: identifi cation of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol 2013; 70: 1359–66.

103 Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013; 9: 445–54.

104 Bezard E, Przedborski S. A tale on animal models of Parkinson’s disease. Mov Disord 2011; 26: 993–1002.

105 Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33: 599–614.

106 Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 2008; 14: 504–06.

107 Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 2008; 23: 2303–06.

108 Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501–03.

109 Visanji NP, Brooks PL, Hazrati L-N, Lang AE. The prion hypothesis in Parkinson’s disease: Braak to the future. Acta Neuropathol Commun 2013; 1: 2.

110 Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VMY. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012; 209: 975–86.

111 Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949–53.

112 Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Prion-like spreading of pathological a-synuclein in brain. Brain 2013;136: 1128–38.

113 Sacino AN, Brooks M, McGarvey NH, et al. Induction of CNS alpha-synuclein pathology by fi brillar and non-amyloidogenic recombinant alpha-synuclein. Acta Neuropathol Commun 2013;1: 38.

114 Recasens A, Dehay B, Bove J, et al. Lewy body extracts from Parkinson disease brains trigger a-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014;75: 351–62.

115 Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in Parkinson’s disease. J Biol Chem 2012;288: 10736–41.

116 Chen X, Wu G, Schwarzschild MA. Urate in Parkinson’s disease:more than a biomarker? Curr Neurol Neurosci Rep 2012; 12: 367–75.

117 Greenamyre JT, Hastings TG. Biomedicine. Parkinson’s—divergent causes, convergent mechanisms. Science 2004; 304: 1120–22.

118 Sian-Hulsmann J, Mandel S, Youdim MBH, Riederer P. The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem 2011; 118: 939–57.

119 Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001;57: 1497–99.

120 Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33–39.

121 Berg D, Lang AE, Postuma RB, et al. Changing the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities. Lancet Neurol 2013; 12: 514–24.

122 Berg D, Postuma RB, Bloem B, et al. Time to redefi ne PD? Introductory statement of the MDS Task Force on the defi nition of Parkinson’s disease. Mov Disord 2014; 29: 454–62.

123 Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931–38.

124 Fahn S, Oakes D, Shoulson I, et al, and the Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004; 351: 2498–508.

125 Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007; 69: 1480–90.

126 Whone AL, Watts RL, Stoessl AJ, et al, and the REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93–101.

127 Brooks DJ, Pavese N. Imaging biomarkers in Parkinson’s disease. Prog Neurobiol 2011; 95: 614–28.

128 Marek K, Seibyl J, Eberly S, et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014; 82: 1791–97.

129 Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 2014; 29: 1767–73.

130 Salsone M, Labate A, Quattrone A. Cardiac denervation precedes nigrostriatal damage in idiopathic rapid eye movement sleep behavior disorder. Mov Disord 2012; 27: 1068–69.

131 Iranzo A, Gelpi E, Tolosa E, et al. Neuropathology of prodromal Lewy body disease. Mov Disord 2014; 29: 410–15.

132 Lehericy S, Sharman MA, Santos CLD, Paquin R, Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson’s disease. Mov Disord 2012; 27: 822–30.

133 Cochrane CJ, Ebmeier KP. Diff usion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 2013; 80: 857–64.

134 Lehericy S, Bardinet E, Poupon C, Vidailhet M, Francois C. 7 tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson’s disease. Mov Disord 2014; 29: 1574–81.

135 Visanji NP, Marras C, Hazrati L-N, Liu LWC, Lang AE. Alimentary, my dear Watson? The challenges of enteric a-synuclein as a Parkinson’s disease biomarker. Mov Disord 2014; 29: 444–50.

136 Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Mov Disord 2012;27: 716–19.

137 Bottner M, Zorenkov D, Hellwig I, et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis 2012; 48: 474–80.

138 Gold A, Turkalp ZT, Munoz DG. Enteric alpha-synuclein expression is increased in Parkinson’s disease but not Alzheimer’s disease. Mov Disord 2013; 28: 237–41.

139 Visanji NP, Marras C, Kern DS, et al. Colonic mucosal a-synuclein lacks specifi city as a biomarker for Parkinson disease. Neurology 2015; 84: 609–16.

140 Donadio V, Incensi A, Leta V, et al. Skin nerve a-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 2014;82: 1362–69.

141 Hong Z, Shi M, Chung KA, et al. DJ-1 and a-synuclein in human cerebrospinal fl uid as biomarkers of Parkinson’s disease. Brain 2010; 133: 713–26.

142 Parnetti L, Castrioto A, Chiasserini D, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013; 9: 131–40.

143 Eller M, Williams DR. Biological fl uid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 2009; 5: 561–70.

144 Stewart T, Sui Y-T, Gonzalez-Cuyar LF, et al. Cheek cell–derived a-synuclein and DJ-1 do not diff erentiate Parkinson’s disease from control. Neurobiol Aging 2014; 35: 418–20.

145 Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain 2008;131: 389–96.

146 Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69: 570–80.

147 Aldakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease modifying therapies in Parkinson disease. Neurother 2014; 11: 6–23.

148 Tran HT, Chung CH-Y, Iba M, et al. a-Synuclein immunotherapy blocks uptake and templated propagation of misfolded a-synuclein and neurodegeneration. Cell Rep 2014; 7: 2054–65.

149 Coune PG, Schneider BL, Aebischer P. Parkinson’s disease: gene therapies. Cold Spring Harb Perspect Med 2012; 2: a009431.

150 Kordower JH, Bjorklund A. Trophic factor gene therapy for Parkinson’s disease. Mov Disord 2013; 28: 96–109.

151 Bjorklund A, Kordower JH. Cell therapy for Parkinson’s disease: what next? Mov Disord 2013; 28: 110–15.

152 Lindvall O. Developing dopaminergic cell therapy for Parkinson’s disease—give up or move forward? Mov Disord 2013; 28: 268–73.

153 Charles D, Konrad PE, Neimat JS, et al. Subthalamic nucleus deep brain stimulation in early stage Parkinson’s disease. Parkinsonism Relat Disord 2014; 20: 731–37.

154 Fox SH, Katzenschlager R, Lim S-Y, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011; 26: S2–41.

155 Connolly B, Lang AE. Pharmacological treatment of Parkinson’s disease: a review. JAMA 2014; 311: 1670–83.

156 PD MED Collaborative Group. Long-term eff ectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014;384: 1196–205.

157 Lang AE, Marras C. Initiating dopaminergic treatment in Parkinson’s disease. Lancet 2014; 384: 1164–66.

158 Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fl uctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013; 12: 346–56.

159 Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13: 141–49.

160 Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. Mov Disord 2013; 28: 131–44.

161 Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59 (suppl 3): 3–7.

162 Burn D, Emre M, McKeith I, et al. Eff ects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21: 1899–907.

163 Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383: 533–40.

164 Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011;26: S42–80.

165 Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229–36.

166 Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–80.

167 Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord 2011; 26: 2496–503.

168 Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–18.

169 Chung KA, Lobb BM, Nutt JG, Horak FB. Eff ects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; 75: 1263–69.

170 Henderson EJ, Lord SR, Close JC, Lawrence AD, Whone A, Ben-Shlomo Y. The respond trial—rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo

controlled trial to evaluate the eff ect of rivastigmine on gait in patients with Parkinson’s disease who have fallen. BMC Neurol 2013; 13: 188.

171 Kalia SK, Sankar T, Lozano AM. Deep brain stimulation for Parkinson’s disease and other movement disorders. Curr Opin Neurol 2013; 26: 374–80.

172 Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson’s disease with deep brain stimulation. Lancet Neurol 2012; 11: 429–42.

173 Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early mo tor complications. N Engl J Med 2013; 368: 610–22.

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí